JPRN-UMIN000018563已完成未知
A study of the efficacy of preoperative chemotherapy and radiation therapy for rectal cancer - A study of the efficacy of preoperative chemotherapy and radiation therapy for rectal cancer
Tokyo Women's Medical University Hospital0 个研究点目标入组 40 人开始时间: 2015年8月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
The completion rate of CRT was high at 94% (n=29/31). The downstaging rate of CRT was 61% (n=19/31). The pathological complete response rate was 6.5% (n=2/31). Significant differences were observed in the 3-year local recurrence rate between the two groups (P<0.05).
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Preoperative diagnosis of rectal cancer in M or MP and N0 Stage I (Japanese Classification of Colorectal Carcinoma the 7th edition) (2)Patients who principal investigator has determined to be inappropriate as a subject
研究者
相似试验
已完成
2 期
A phase III randomized study of neoadjuvant chemotherapy including trastuzumab + cyclophosphamide + docetaxel in patients with operable HER2 positive breast cancer (JBCRG 10)HER2 positive breast cancerJPRN-UMIN000002365Japan Breast Cancer Research Group (JBCRG)103
已完成
2 期
Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + Low-Dose CPA Combination Therapy for Nonresponders to EXE Therapy.(JBCRG-11CPA)ER positive, HER2 negative, Stage II or IIIA [T2-3,N0-2,M0], Primary Postmenopausal Invasive Breast Cancer PatientsJPRN-UMIN000004751Japan Breast Cancer Research Group (JBCRG)59
已完成
不适用
Feasibility study of CBDCA+TS-1 adjuvant therapy for p-stage IB(T2a>4cm)/II/IIIA non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000009101Osaka University Graduate School of Medicine35
终止
2 期
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation TherapyPancreatic CancerNCT00766636M.D. Anderson Cancer Center5
已完成
1 期
The Feasibility Study of Adjuvant Chemotherapy with TS-1+Carboplatin followed by TS-1 maintenace in Patients with Completely Resected Stage II-IIIA Non-Small-Cell Lung Canceron-small-cell lung cancerJPRN-UMIN000005041Setouchi Lung Cancer Group89